Should Patients with Low-Risk Myelodysplastic Syndrome be Treated Earlier in the Course of Their Disease? Eric J. Feldman CLINICAL TRIAL REPORT 16 December 2010 Pages: 1 - 2
Survival Advantage in CLL with Frontline FCR Therapy Susan O’Brien CLINICAL TRIAL REPORT 29 December 2010 Pages: 3 - 4
Therapeutic Modalities for Patients with Lower-Risk Myelodysplastic Syndromes: Current Options and Future Directions Shyamala C. NavadaLewis R. Silverman ReviewPaper 14 December 2010 Pages: 5 - 12
The Search for Better Prognostic Models in Myelodysplastic Syndromes Fabio P. S. SantosHagop KantarjianFarhad Ravandi ReviewPaper 07 December 2010 Pages: 13 - 21
Future Therapies for the Myeloproliferative Neoplasms Robyn ScherberRuben A. Mesa ReviewPaper 16 November 2010 Pages: 22 - 27
Special Issues in Myeloproliferative Neoplasms Tiziano BarbuiGuido Finazzi ReviewPaper 23 December 2010 Pages: 28 - 35
What is the Best Frontline Therapy for Patients with CLL and 17p Deletion? Xavier C. BadouxMichael J. KeatingWilliam G. Wierda ReviewPaper 14 December 2010 Pages: 36 - 46
The Role of Transplantation in Diffuse Large B-Cell Lymphoma: The Impact of Rituximab Plus Chemotherapy in First-line and Relapsed Settings Celso Arrais RodriguesPoliana Alves PatahMarcos de Lima ReviewPaper 30 December 2010 Pages: 47 - 57
Burkitt Lymphoma and Atypical Burkitt or Burkitt-like Lymphoma: Should These be Treated as Different Diseases? Deborah A. ThomasSusan O’BrienHagop Kantarjian ReviewPaper 31 December 2010 Pages: 58 - 66
The Emerging Role of Histone Deacetylase Inhibitors in Treating T-cell Lymphomas Steven M. Horwitz ReviewPaper 16 November 2010 Pages: 67 - 72